Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02162979|
Recruitment Status : Terminated (Not enough subjects.)
First Posted : June 13, 2014
Results First Posted : July 22, 2014
Last Update Posted : March 30, 2018
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease||Drug: sildenafil Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease|
|Study Start Date :||February 2002|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||January 2009|
subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil 50mg BID for 2 weeks
Other Name: Viagra
Placebo Comparator: Placebo comparator
subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
- Change in Duration of Dyskinesia. [ Time Frame: 2 weeks ]
- Percent Change in "on" Time [ Time Frame: 4 weeks ]"on" time is the period in which the subject is symptom free. We will track the amount of time the subject is considered symptom free before and after treatment. This value will be represented as a percent change.
- Change in Dose of Anti-parkinsonian Medications [ Time Frame: 7 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02162979
|United States, California|
|Loma Linda University|
|Loma Linda, California, United States, 92354|
|Principal Investigator:||David M. Swope, MD||Loma Linda University|